Comprehensive preventive treatments for episodic migraine: a systematic review of randomized clinical trials.

Researchers conducted a comprehensive review of 39 randomized controlled trials involving over 15,000 people to compare different treatments for preventing episodic migraine attacks. Episodic migraine is a common neurological condition that significantly affects quality of life and work productivity. The study examined both medication-based and non-medication approaches, including acupuncture, to see which treatments best reduced the number of migraine days per month, reduced headache days, and minimized side effects.

The review found that newer medications called anti-CGRP antibodies and gepants were most effective at reducing monthly migraine days (by 3.2 to 4.4 days) with relatively few side effects. Traditional medications like topiramate and propranolol helped somewhat but caused more side effects. Combination treatments worked well but also increased the likelihood of unwanted effects.

Importantly for acupuncture patients, the researchers found that non-pharmacological interventions, including acupuncture and neuromodulation devices, showed promising results as part of migraine prevention strategies. While these approaches lacked standardization across studies, they were identified as useful additions to treatment plans. The authors concluded that individualized, multimodal preventive strategies—meaning combining different types of treatments tailored to each person—offer the best approach to managing episodic migraines.

What this means for you: Acupuncture may serve as a valuable component of your migraine prevention plan, particularly when combined with other evidence-based treatments. The review supports using multiple treatment approaches rather than relying on medication alone. To ensure optimal results, seek care from a licensed acupuncturist with experience treating migraine patients.

This systematic review and meta-analysis examined 39 RCTs comprising over 15,000 patients with episodic migraine, following PRISMA guidelines. Primary outcomes included monthly migraine days (MMD), monthly headache days (MHD), acute medication days (AMD), and adverse events. Meta-analysis of allopathic treatments demonstrated significant MMD reduction versus placebo (-1.25 days; 95% CI -1.47 to -1.04; p<0.001). Anti-CGRP monoclonal antibodies and gepants showed superior efficacy with MMD reductions of -3.2 to -4.4 days and favorable safety profiles. Traditional prophylactic agents (topiramate, propranolol) demonstrated modest efficacy with higher adverse event rates. Combination therapies achieved MMD reductions up to -5.1 days but increased side effects. Non-pharmacological interventions including acupuncture and neuromodulation showed promising results, though standardization was lacking. Clinical takeaway: Acupuncture represents a viable adjunctive therapy within individualized, multimodal preventive strategies for episodic migraine, particularly relevant for patients seeking reduced pharmacological burden or in resource-limited settings.